Rheumatologic manifestations of sarcoidosis and increased risk of spondyloarthritis occurrence. A retrospective single center case-control study

An association between sarcoidosis and spondyloarthritis (SpA) has already been reported. The prevalence of sacroiliitis in sarcoidosis was estimated between 6.6% and 23.4%. All patients with sacroiliitis were diagnosed with SpA according to the Assessment of SpondyloArthritis International Society...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2021-12, Vol.88 (6), p.105247-105247, Article 105247
Hauptverfasser: Deroualle, Tiffany, Dominique, Stéphane, Monti, Francesco, Grosjean, Julien, Darmoni, Stéfan, Lequerré, Thierry, Vittecoq, Olivier
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 105247
container_issue 6
container_start_page 105247
container_title Joint, bone, spine : revue du rhumatisme
container_volume 88
creator Deroualle, Tiffany
Dominique, Stéphane
Monti, Francesco
Grosjean, Julien
Darmoni, Stéfan
Lequerré, Thierry
Vittecoq, Olivier
description An association between sarcoidosis and spondyloarthritis (SpA) has already been reported. The prevalence of sacroiliitis in sarcoidosis was estimated between 6.6% and 23.4%. All patients with sacroiliitis were diagnosed with SpA according to the Assessment of SpondyloArthritis International Society (ASAS) classification criteria. However, sacroiliac joint involvement has been described in sarcoidosis without associated SpA.This association led us to determine a clinical form of sarcoidosis predictive of SpA development and to evaluate their respective management.We conducted a retrospective, single-center, multiparameter, case-control study that enrolled patients with a sarcoidosis/SpA sequence, followed up between 1992 and 2018, who were randomly matched to patients with sarcoidosis without SpA development during the same period. Identification of patients was performed via a semantic query in the database of the Normandy Clinical Data Warehouse (NCDW). The diagnoses of sarcoidosis and SpA were based on ATS/ERS/WASOG and ASAS diagnostic and classification criteria, respectively. The number of events was gathered under one entity based on sarcoidosis organ involvement. The predictive effect of different variables, collected at the time of sarcoidosis diagnosis, on SpA occurrence was studied using conditional logistic regression models (PROC PHREG). This study has been approved by the local Institutional Review Board (E2020-91). Twenty-two patients with a sarcoidosis/SpA sequence were identified; 66 controls were selected. The proportion of organ involvement related to sarcoidosis was similar between the two groups except for rheumatologic manifestations. In cases, the mean (SD) delay to SpA diagnosis was 7.7 years [range 0–25]. The occurrence of SpA was significantly associated with the rheumatologic involvement of sarcoidosis (OR 6.42 95%CI [2.30–19.59] P < 0.01 after Bonferroni's correction). This association remained significant in our age- and sex-adjusted model (OR 5.36 95%CI [1.80–17.19] P < 0.05). No specific rheumatologic clinical picture could be identified, but axial involvement, corresponding to inflammatory back pain and alternating buttock pain, was more frequently observed in cases, resulting in a higher proportion of patients presenting a combined pattern of axial and peripheral involvement. SpA characteristics of patients with sarcoidosis developing SpA are summarized in Appendix A.
doi_str_mv 10.1016/j.jbspin.2021.105247
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03985695v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1297319X21001202</els_id><sourcerecordid>2548403519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c322t-df28c8d110ba221eb6c4fd0510f75aeafb9ef8c29712740781462b295e7c41f13</originalsourceid><addsrcrecordid>eNp9kc1q3DAURk1paX7aN-hCy3bhqSRLlr0pDCFtAgOB0EB3QpauMpp6JFeSB-Yt-siR69JlVxKXcz-456uqDwRvCCbt58PmMKTJ-Q3FlJQRp0y8qi6JEF0tKGevy5_2om5I_-OiukrpgDFuKG_fVhcNo6QVnF1Wvx_3MB9VDmN4dhodlXcWUlbZBZ9QsCipqIMzIbmElDfIeR1BJTAouvTzDzEFb85jUDHvo8uFC1rPMYLXsEFbFCHHkCbQ2Z0AJeefR0AafIaIdEmqdfCFGFHKszm_q95YNSZ4__e9rp6-3n6_uat3D9_ub7a7WjeU5tpY2unOEIIHRSmBodXMGswJtoIrUHbowXa6CCBUMCw6wlo60J6D0IxY0lxXn9bcvRrlFN1RxbMMysm77U4uM9z0HW97flrYjys7xfBrLnrk0SUN46g8hDnJYrtjuOGkLyhbUV1uThHsv2yC5dKbPMi1N7n0JtfeytqXdQ3KyScHUSbtFoHGxSJOmuD-H_AC65qkrg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548403519</pqid></control><display><type>article</type><title>Rheumatologic manifestations of sarcoidosis and increased risk of spondyloarthritis occurrence. A retrospective single center case-control study</title><source>Elsevier ScienceDirect Journals</source><creator>Deroualle, Tiffany ; Dominique, Stéphane ; Monti, Francesco ; Grosjean, Julien ; Darmoni, Stéfan ; Lequerré, Thierry ; Vittecoq, Olivier</creator><creatorcontrib>Deroualle, Tiffany ; Dominique, Stéphane ; Monti, Francesco ; Grosjean, Julien ; Darmoni, Stéfan ; Lequerré, Thierry ; Vittecoq, Olivier</creatorcontrib><description>An association between sarcoidosis and spondyloarthritis (SpA) has already been reported. The prevalence of sacroiliitis in sarcoidosis was estimated between 6.6% and 23.4%. All patients with sacroiliitis were diagnosed with SpA according to the Assessment of SpondyloArthritis International Society (ASAS) classification criteria. However, sacroiliac joint involvement has been described in sarcoidosis without associated SpA.This association led us to determine a clinical form of sarcoidosis predictive of SpA development and to evaluate their respective management.We conducted a retrospective, single-center, multiparameter, case-control study that enrolled patients with a sarcoidosis/SpA sequence, followed up between 1992 and 2018, who were randomly matched to patients with sarcoidosis without SpA development during the same period. Identification of patients was performed via a semantic query in the database of the Normandy Clinical Data Warehouse (NCDW). The diagnoses of sarcoidosis and SpA were based on ATS/ERS/WASOG and ASAS diagnostic and classification criteria, respectively. The number of events was gathered under one entity based on sarcoidosis organ involvement. The predictive effect of different variables, collected at the time of sarcoidosis diagnosis, on SpA occurrence was studied using conditional logistic regression models (PROC PHREG). This study has been approved by the local Institutional Review Board (E2020-91). Twenty-two patients with a sarcoidosis/SpA sequence were identified; 66 controls were selected. The proportion of organ involvement related to sarcoidosis was similar between the two groups except for rheumatologic manifestations. In cases, the mean (SD) delay to SpA diagnosis was 7.7 years [range 0–25]. The occurrence of SpA was significantly associated with the rheumatologic involvement of sarcoidosis (OR 6.42 95%CI [2.30–19.59] P &lt; 0.01 after Bonferroni's correction). This association remained significant in our age- and sex-adjusted model (OR 5.36 95%CI [1.80–17.19] P &lt; 0.05). No specific rheumatologic clinical picture could be identified, but axial involvement, corresponding to inflammatory back pain and alternating buttock pain, was more frequently observed in cases, resulting in a higher proportion of patients presenting a combined pattern of axial and peripheral involvement. SpA characteristics of patients with sarcoidosis developing SpA are summarized in Appendix A.</description><identifier>ISSN: 1297-319X</identifier><identifier>EISSN: 1778-7254</identifier><identifier>DOI: 10.1016/j.jbspin.2021.105247</identifier><identifier>PMID: 34216754</identifier><language>eng</language><publisher>Elsevier Masson SAS</publisher><subject>Computer Science ; Human health and pathology ; Life Sciences ; Rhumatology and musculoskeletal system ; Santé publique et épidémiologie</subject><ispartof>Joint, bone, spine : revue du rhumatisme, 2021-12, Vol.88 (6), p.105247-105247, Article 105247</ispartof><rights>2021 Société française de rhumatologie</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c322t-df28c8d110ba221eb6c4fd0510f75aeafb9ef8c29712740781462b295e7c41f13</cites><orcidid>0000-0002-7162-318X ; 0000-0002-7446-644X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jbspin.2021.105247$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://hal.science/hal-03985695$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Deroualle, Tiffany</creatorcontrib><creatorcontrib>Dominique, Stéphane</creatorcontrib><creatorcontrib>Monti, Francesco</creatorcontrib><creatorcontrib>Grosjean, Julien</creatorcontrib><creatorcontrib>Darmoni, Stéfan</creatorcontrib><creatorcontrib>Lequerré, Thierry</creatorcontrib><creatorcontrib>Vittecoq, Olivier</creatorcontrib><title>Rheumatologic manifestations of sarcoidosis and increased risk of spondyloarthritis occurrence. A retrospective single center case-control study</title><title>Joint, bone, spine : revue du rhumatisme</title><description>An association between sarcoidosis and spondyloarthritis (SpA) has already been reported. The prevalence of sacroiliitis in sarcoidosis was estimated between 6.6% and 23.4%. All patients with sacroiliitis were diagnosed with SpA according to the Assessment of SpondyloArthritis International Society (ASAS) classification criteria. However, sacroiliac joint involvement has been described in sarcoidosis without associated SpA.This association led us to determine a clinical form of sarcoidosis predictive of SpA development and to evaluate their respective management.We conducted a retrospective, single-center, multiparameter, case-control study that enrolled patients with a sarcoidosis/SpA sequence, followed up between 1992 and 2018, who were randomly matched to patients with sarcoidosis without SpA development during the same period. Identification of patients was performed via a semantic query in the database of the Normandy Clinical Data Warehouse (NCDW). The diagnoses of sarcoidosis and SpA were based on ATS/ERS/WASOG and ASAS diagnostic and classification criteria, respectively. The number of events was gathered under one entity based on sarcoidosis organ involvement. The predictive effect of different variables, collected at the time of sarcoidosis diagnosis, on SpA occurrence was studied using conditional logistic regression models (PROC PHREG). This study has been approved by the local Institutional Review Board (E2020-91). Twenty-two patients with a sarcoidosis/SpA sequence were identified; 66 controls were selected. The proportion of organ involvement related to sarcoidosis was similar between the two groups except for rheumatologic manifestations. In cases, the mean (SD) delay to SpA diagnosis was 7.7 years [range 0–25]. The occurrence of SpA was significantly associated with the rheumatologic involvement of sarcoidosis (OR 6.42 95%CI [2.30–19.59] P &lt; 0.01 after Bonferroni's correction). This association remained significant in our age- and sex-adjusted model (OR 5.36 95%CI [1.80–17.19] P &lt; 0.05). No specific rheumatologic clinical picture could be identified, but axial involvement, corresponding to inflammatory back pain and alternating buttock pain, was more frequently observed in cases, resulting in a higher proportion of patients presenting a combined pattern of axial and peripheral involvement. SpA characteristics of patients with sarcoidosis developing SpA are summarized in Appendix A.</description><subject>Computer Science</subject><subject>Human health and pathology</subject><subject>Life Sciences</subject><subject>Rhumatology and musculoskeletal system</subject><subject>Santé publique et épidémiologie</subject><issn>1297-319X</issn><issn>1778-7254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc1q3DAURk1paX7aN-hCy3bhqSRLlr0pDCFtAgOB0EB3QpauMpp6JFeSB-Yt-siR69JlVxKXcz-456uqDwRvCCbt58PmMKTJ-Q3FlJQRp0y8qi6JEF0tKGevy5_2om5I_-OiukrpgDFuKG_fVhcNo6QVnF1Wvx_3MB9VDmN4dhodlXcWUlbZBZ9QsCipqIMzIbmElDfIeR1BJTAouvTzDzEFb85jUDHvo8uFC1rPMYLXsEFbFCHHkCbQ2Z0AJeefR0AafIaIdEmqdfCFGFHKszm_q95YNSZ4__e9rp6-3n6_uat3D9_ub7a7WjeU5tpY2unOEIIHRSmBodXMGswJtoIrUHbowXa6CCBUMCw6wlo60J6D0IxY0lxXn9bcvRrlFN1RxbMMysm77U4uM9z0HW97flrYjys7xfBrLnrk0SUN46g8hDnJYrtjuOGkLyhbUV1uThHsv2yC5dKbPMi1N7n0JtfeytqXdQ3KyScHUSbtFoHGxSJOmuD-H_AC65qkrg</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Deroualle, Tiffany</creator><creator>Dominique, Stéphane</creator><creator>Monti, Francesco</creator><creator>Grosjean, Julien</creator><creator>Darmoni, Stéfan</creator><creator>Lequerré, Thierry</creator><creator>Vittecoq, Olivier</creator><general>Elsevier Masson SAS</general><general>Elsevier Masson</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-7162-318X</orcidid><orcidid>https://orcid.org/0000-0002-7446-644X</orcidid></search><sort><creationdate>202112</creationdate><title>Rheumatologic manifestations of sarcoidosis and increased risk of spondyloarthritis occurrence. A retrospective single center case-control study</title><author>Deroualle, Tiffany ; Dominique, Stéphane ; Monti, Francesco ; Grosjean, Julien ; Darmoni, Stéfan ; Lequerré, Thierry ; Vittecoq, Olivier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c322t-df28c8d110ba221eb6c4fd0510f75aeafb9ef8c29712740781462b295e7c41f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Computer Science</topic><topic>Human health and pathology</topic><topic>Life Sciences</topic><topic>Rhumatology and musculoskeletal system</topic><topic>Santé publique et épidémiologie</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deroualle, Tiffany</creatorcontrib><creatorcontrib>Dominique, Stéphane</creatorcontrib><creatorcontrib>Monti, Francesco</creatorcontrib><creatorcontrib>Grosjean, Julien</creatorcontrib><creatorcontrib>Darmoni, Stéfan</creatorcontrib><creatorcontrib>Lequerré, Thierry</creatorcontrib><creatorcontrib>Vittecoq, Olivier</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Joint, bone, spine : revue du rhumatisme</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deroualle, Tiffany</au><au>Dominique, Stéphane</au><au>Monti, Francesco</au><au>Grosjean, Julien</au><au>Darmoni, Stéfan</au><au>Lequerré, Thierry</au><au>Vittecoq, Olivier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rheumatologic manifestations of sarcoidosis and increased risk of spondyloarthritis occurrence. A retrospective single center case-control study</atitle><jtitle>Joint, bone, spine : revue du rhumatisme</jtitle><date>2021-12</date><risdate>2021</risdate><volume>88</volume><issue>6</issue><spage>105247</spage><epage>105247</epage><pages>105247-105247</pages><artnum>105247</artnum><issn>1297-319X</issn><eissn>1778-7254</eissn><abstract>An association between sarcoidosis and spondyloarthritis (SpA) has already been reported. The prevalence of sacroiliitis in sarcoidosis was estimated between 6.6% and 23.4%. All patients with sacroiliitis were diagnosed with SpA according to the Assessment of SpondyloArthritis International Society (ASAS) classification criteria. However, sacroiliac joint involvement has been described in sarcoidosis without associated SpA.This association led us to determine a clinical form of sarcoidosis predictive of SpA development and to evaluate their respective management.We conducted a retrospective, single-center, multiparameter, case-control study that enrolled patients with a sarcoidosis/SpA sequence, followed up between 1992 and 2018, who were randomly matched to patients with sarcoidosis without SpA development during the same period. Identification of patients was performed via a semantic query in the database of the Normandy Clinical Data Warehouse (NCDW). The diagnoses of sarcoidosis and SpA were based on ATS/ERS/WASOG and ASAS diagnostic and classification criteria, respectively. The number of events was gathered under one entity based on sarcoidosis organ involvement. The predictive effect of different variables, collected at the time of sarcoidosis diagnosis, on SpA occurrence was studied using conditional logistic regression models (PROC PHREG). This study has been approved by the local Institutional Review Board (E2020-91). Twenty-two patients with a sarcoidosis/SpA sequence were identified; 66 controls were selected. The proportion of organ involvement related to sarcoidosis was similar between the two groups except for rheumatologic manifestations. In cases, the mean (SD) delay to SpA diagnosis was 7.7 years [range 0–25]. The occurrence of SpA was significantly associated with the rheumatologic involvement of sarcoidosis (OR 6.42 95%CI [2.30–19.59] P &lt; 0.01 after Bonferroni's correction). This association remained significant in our age- and sex-adjusted model (OR 5.36 95%CI [1.80–17.19] P &lt; 0.05). No specific rheumatologic clinical picture could be identified, but axial involvement, corresponding to inflammatory back pain and alternating buttock pain, was more frequently observed in cases, resulting in a higher proportion of patients presenting a combined pattern of axial and peripheral involvement. SpA characteristics of patients with sarcoidosis developing SpA are summarized in Appendix A.</abstract><pub>Elsevier Masson SAS</pub><pmid>34216754</pmid><doi>10.1016/j.jbspin.2021.105247</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7162-318X</orcidid><orcidid>https://orcid.org/0000-0002-7446-644X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1297-319X
ispartof Joint, bone, spine : revue du rhumatisme, 2021-12, Vol.88 (6), p.105247-105247, Article 105247
issn 1297-319X
1778-7254
language eng
recordid cdi_hal_primary_oai_HAL_hal_03985695v1
source Elsevier ScienceDirect Journals
subjects Computer Science
Human health and pathology
Life Sciences
Rhumatology and musculoskeletal system
Santé publique et épidémiologie
title Rheumatologic manifestations of sarcoidosis and increased risk of spondyloarthritis occurrence. A retrospective single center case-control study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T21%3A46%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rheumatologic%20manifestations%20of%20sarcoidosis%20and%20increased%20risk%20of%20spondyloarthritis%20occurrence.%20A%20retrospective%20single%20center%20case-control%20study&rft.jtitle=Joint,%20bone,%20spine%20:%20revue%20du%20rhumatisme&rft.au=Deroualle,%20Tiffany&rft.date=2021-12&rft.volume=88&rft.issue=6&rft.spage=105247&rft.epage=105247&rft.pages=105247-105247&rft.artnum=105247&rft.issn=1297-319X&rft.eissn=1778-7254&rft_id=info:doi/10.1016/j.jbspin.2021.105247&rft_dat=%3Cproquest_hal_p%3E2548403519%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548403519&rft_id=info:pmid/34216754&rft_els_id=S1297319X21001202&rfr_iscdi=true